EP1436406A4 - Procede de modulation ou d'examen des taux de ku70 dans des cellules - Google Patents
Procede de modulation ou d'examen des taux de ku70 dans des cellulesInfo
- Publication number
- EP1436406A4 EP1436406A4 EP02761739A EP02761739A EP1436406A4 EP 1436406 A4 EP1436406 A4 EP 1436406A4 EP 02761739 A EP02761739 A EP 02761739A EP 02761739 A EP02761739 A EP 02761739A EP 1436406 A4 EP1436406 A4 EP 1436406A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- bax
- cells
- examining
- levels
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
L'invention concerne un procédé permettant de prédire si des cellules répondront à des thérapies à médiation par apoptose régulée à l'aide de la protéine Bax. Dans un mode de réalisation de cette invention, le procédé comprend les étapes consistant: (a) à examiner l'intensité de l'expression de la protéine Bax ou de l'ARNm Bax dans une cellule par rapport à un contrôle, et (b) en fonction de ce niveau d'intensité, à prédire si ces cellules répondront à des thérapies à médiation par apoptose régulée à l'aide de la protéine Bax, un taux élevé de Bax indiquant que les taux de Ku70 peuvent être abaissés et la sensibilité à l'apoptose augmentée. Dans un autre mode de réalisation, l'invention concerne un procédé de sensibilisation des cellules à une thérapie du cancer, lequel comprend l'étape consistant à réduire le taux de protéine Ku70 natif de la cellule. Dans un autre mode de réalisation encore, l'invention concerne une méthode de traitement de maladies liées à la mort cellulaire, qui comprend l'étape consistant à augmenter le taux de protéine Ku70 cellulaire.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32429201P | 2001-09-24 | 2001-09-24 | |
US324292P | 2001-09-24 | ||
US36428702P | 2002-03-14 | 2002-03-14 | |
US364287P | 2002-03-14 | ||
US37858502P | 2002-05-08 | 2002-05-08 | |
US378585P | 2002-05-08 | ||
PCT/US2002/029737 WO2003027237A2 (fr) | 2001-09-24 | 2002-09-19 | Procede de modulation ou d'examen des taux de ku70 dans des cellules |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1436406A2 EP1436406A2 (fr) | 2004-07-14 |
EP1436406A4 true EP1436406A4 (fr) | 2004-10-13 |
Family
ID=27406324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02761739A Withdrawn EP1436406A4 (fr) | 2001-09-24 | 2002-09-19 | Procede de modulation ou d'examen des taux de ku70 dans des cellules |
Country Status (4)
Country | Link |
---|---|
US (3) | US20030073661A1 (fr) |
EP (1) | EP1436406A4 (fr) |
AU (1) | AU2002326980A1 (fr) |
WO (1) | WO2003027237A2 (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003074667A2 (fr) * | 2002-03-01 | 2003-09-12 | Blood Center Research Foundation | Peptides reducteur de bax derives de ku-70 et leur utilisation dans la protection des cellules endommagees |
US20080096824A1 (en) * | 2003-02-28 | 2008-04-24 | Shigemi Matsuyama | Ku-70-derived bax-suppressing peptides and use thereof for the protection of damaged cells |
CN104541170A (zh) * | 2012-05-10 | 2015-04-22 | 尤特罗皮克斯制药股份有限公司 | 对癌症的代理功能性诊断测试 |
IN2014DN11205A (fr) | 2012-06-20 | 2015-10-02 | Eutropics Pharmaceuticals Inc | |
WO2014081953A1 (fr) | 2012-11-21 | 2014-05-30 | Richard David J | Méthodes et compositions utiles dans le traitement de maladies faisant appel à des protéines de la famille bcl-2 et des dérivés d'isoquinoléine et de quinoléine |
CN105555956B (zh) * | 2013-07-09 | 2020-05-15 | 中央兰开夏大学 | 针对神经胶质瘤细胞的适体 |
US10732182B2 (en) | 2013-08-01 | 2020-08-04 | Eutropics Pharmaceuticals, Inc. | Method for predicting cancer sensitivity |
US10640803B2 (en) | 2013-10-30 | 2020-05-05 | Eutropics Pharmaceuticals, Inc. | Methods for determining chemosensitivity and chemotoxicity |
EP3245301B1 (fr) | 2015-01-12 | 2020-11-11 | Eutropics Pharmaceuticals, Inc. | Essai de diagnostic dépendant du contexte pour guider le traitement du cancer |
CA2982928A1 (fr) | 2015-04-20 | 2016-10-27 | Tolero Pharmaceuticals, Inc. | Prediction de la reaction a l'alvocidib par identification de profil mitochondrial |
CN111349118B (zh) | 2015-05-18 | 2023-08-22 | 住友制药肿瘤公司 | 具有增加的生物利用度的阿伏西地前药 |
CA2993659A1 (fr) | 2015-08-03 | 2017-02-09 | Tolero Pharmaceuticals, Inc. | Therapies combinatoires pour le traitement du cancer |
WO2018094275A1 (fr) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Promédicaments de l'alvocidib et leur utilisation en tant qu'inhibiteurs de protéines kinases |
EP3362471B1 (fr) | 2016-12-19 | 2021-11-17 | Sumitomo Dainippon Pharma Oncology, Inc. | Peptides profilants et procédés de profilage de sensibilité |
WO2019055579A1 (fr) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | Régime de traitement pour des cancers qui sont insensibles aux inhibiteurs de bcl-2 à l'aide de l'inhibiteur de mcl-1 alvocidib |
KR20210099066A (ko) | 2018-12-04 | 2021-08-11 | 스미토모 다이니폰 파마 온콜로지, 인크. | 암의 치료를 위한 작용제로서 사용하기 위한 cdk9 억제제 및 그의 다형체 |
JP2022525149A (ja) | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置 |
CN114392345B (zh) * | 2021-03-11 | 2023-08-25 | 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) | E199l蛋白在促进细胞凋亡中的用途及方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9700574D0 (en) * | 1997-01-13 | 1997-03-05 | Cancer Res Campaign Tech | Methods and means relating to retrotransposon and retroviral integration |
US6399298B1 (en) * | 1998-06-30 | 2002-06-04 | Sloan-Kettering Institute For Cancer Research | Ku70—related methods |
CA2332179C (fr) * | 1998-06-30 | 2011-06-28 | Sloan-Kettering Institute For Cancer Research | Utilisations d'adn-pk |
-
2002
- 2002-09-19 AU AU2002326980A patent/AU2002326980A1/en not_active Abandoned
- 2002-09-19 WO PCT/US2002/029737 patent/WO2003027237A2/fr not_active Application Discontinuation
- 2002-09-19 US US10/247,045 patent/US20030073661A1/en not_active Abandoned
- 2002-09-19 EP EP02761739A patent/EP1436406A4/fr not_active Withdrawn
-
2004
- 2004-08-23 US US10/924,060 patent/US20050026201A1/en not_active Abandoned
-
2006
- 2006-10-13 US US11/580,478 patent/US20070036775A1/en not_active Abandoned
Non-Patent Citations (2)
Title |
---|
SAWADA M ET AL: "Cytoprotective membrane-permeable peptides designed from the Bax-binding domain of Ku70", NATURE CELL BIOLOGY, MACMILLAN PUBLISHERS, GB, vol. 5, no. 4, 24 March 2003 (2003-03-24), pages 352 - 357, XP002967925, ISSN: 1465-7392 * |
SAWADA M.: "Ku70 suppresses cell death by inhibiting mitochondrial translocation of Bax", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 43, March 2002 (2002-03-01), pages 998, XP001182668 * |
Also Published As
Publication number | Publication date |
---|---|
WO2003027237A3 (fr) | 2003-11-06 |
US20070036775A1 (en) | 2007-02-15 |
AU2002326980A1 (en) | 2003-04-07 |
US20050026201A1 (en) | 2005-02-03 |
WO2003027237A2 (fr) | 2003-04-03 |
EP1436406A2 (fr) | 2004-07-14 |
US20030073661A1 (en) | 2003-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003027237A3 (fr) | Procede de modulation ou d'examen des taux de ku70 dans des cellules | |
WO2002069900A3 (fr) | Procede de traitement de troubles proliferatifs d'origine genetique par des inhibiteurs de hsp90 | |
WO2002089747A3 (fr) | Compositions et procedes pour la therapie et le diagnostic du cancer de la prostate | |
WO1996035774A3 (fr) | Fragments d'angiostatine, angiostatine agregee et procedes d'utilisation | |
CA2291892A1 (fr) | Fragments d'angiostatine et leur procede d'utilisation | |
NO973838D0 (no) | DNA-molekyler, deres fremstilling samt anvendelse ved genterapi | |
EP0961833A4 (fr) | Hyaluronidase du plasma humain | |
WO2002074156A3 (fr) | Compositions et procedes de therapie et de diagnostic du cancer du colon | |
ATE313625T1 (de) | ßFUNCTIONAL GENOMICSß UNTER VERWENDUNG VON ZINK FINGER PROTEINEN | |
WO2003102016A3 (fr) | Enzyme inactivant le peptide amyloide pour traiter la maladie d'alzheimer | |
WO2002012328A3 (fr) | Compositions et methodes utilisees dans la therapie et le diagnostic du cancer du colon | |
WO2003031650A3 (fr) | Genes et proteines utilises dans la prevention, la prediction, le pronostic et la therapie de la maladie cardiovasculaire | |
WO2002058534A3 (fr) | Compositions et methodes pour le traitement et le diagnostic du cancer du colon | |
DE69928395D1 (de) | Cyclin-e2 proteine und dafür kodierende gene | |
DE60044350D1 (de) | Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs | |
CA2278808A1 (fr) | Procedes pour la culture de cellules et la multiplication de virus | |
WO2005042719A3 (fr) | Methodes permettant de traiter et de prevenir lesion ischemique au retour de la perfusion a l'aide d'agents interferant avec l'adn | |
WO2002012280A3 (fr) | Compositions et procedes pour le diagnostic et le traitement du cancer du colon | |
WO2005017100A3 (fr) | Ribonucleases et procedes de production de ribonucleases par recombinaison | |
WO1999031128A3 (fr) | Proteines du type facteur humain de necrose tumorale r2 | |
WO2001044448A3 (fr) | Proteines d'oxydoreductase humaines | |
WO2003026494A3 (fr) | Galectines-1 et -4 dans le developpement des tumeurs | |
WO2001094409A3 (fr) | Traitement et diagnostic du cancer du pancreas et compositions a cet effet | |
WO2002101076A3 (fr) | Procedes d'expression ciblee d'un acide nucleique therapeutique | |
WO1998046747A3 (fr) | Genes de la region de non-recombinaison du chromosome y |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040419 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040830 |
|
17Q | First examination report despatched |
Effective date: 20050512 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20051123 |